What is the current stock price of Biofrontera Inc. (BFRI)?

As of the latest market data, Biofrontera Inc. (BFRI) is trading at $1.03. The stock has seen a loss of -0.96% today.

Does Biofrontera Inc. (BFRI) pay a dividend?

Based on current data, Biofrontera Inc. does not have a confirmed active dividend policy.

What is the market cap of Biofrontera Inc.?

The current market capitalization of Biofrontera Inc. (BFRI) is approximately unavailable.

BFRI

Biofrontera Inc.·Healthcare

1.03

0.962%(−0.01)

Market Closed

1.07

3.883%(+0.04)

After Hours

Last Updated: — ET

52W L: $0.5452W H: $1.19

BFRI NEWS

defenseworld.net

Mar 21

Biofrontera Q4 Earnings Call Highlights

Biofrontera (NASDAQ: BFRI) reported record revenue for both the fourth quarter and full year 2025, driven by higher Ameluz photodynamic therapy (PDT) demand and a major change to its U.S. rights and supply economics following an amended arrangement with former parent Biofrontera AG. Record revenue and a profitable fourth quarter CEO Hermann Luebbert said fiscal 2025

seekingalpha.com

Mar 19

Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 19

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.

globenewswire.com

Mar 9

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions.

zacks.com

Mar 9

Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why

Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

globenewswire.com

Mar 9

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

IPO Date

2021-10-29

Beta

0.64

Websitewww.biofrontera.us.com↗